Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
The post Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s appeared first on MedCity News.
